Columbia: Our mission,your dream


Seite 1 von 3
Neuester Beitrag: 25.04.21 02:47
Eröffnet am: 05.01.11 16:33 von: buran Anzahl Beiträge: 55
Neuester Beitrag: 25.04.21 02:47 von: Sarahkciia Leser gesamt: 15.898
Forum: Hot-Stocks   Leser heute: 2
Bewertet mit:
3


 
Seite: < 1 | 2 | 3 >  

246459 Postings, 5865 Tage buranColumbia: Our mission,your dream

 
  
    #1
3
05.01.11 16:33
In the News

12/06/2010
PROCHIEVE Vaginal Progesterone Gel Achieves Primary Endpoint in Phase III Study to Reduce Risk of Preterm Birth

PREGNANT Study Top-line Results Call

11/30/2010
Columbia Laboratories Amends Stockholder Rights Plan to Preserve Use of Net Operating Losses under Section 382

11/04/2010
CBRX Reports Q3 2010 Financial Earning

10/21/2010
Columbia Laboratories to Discuss Q3 2010 Financial Results on Nov. 4 Cconference Call

http://www.columbialabs.com/index.htm  
Angehängte Grafik:
bigchart.png
bigchart.png
29 Postings ausgeblendet.
Seite: < 1 | 2 | 3 >  

246459 Postings, 5865 Tage buranFourth-Quarter-and-Year-End-2013-Financial-Results

 
  
    #31
17.03.14 09:23

246459 Postings, 5865 Tage buranColumbia Laboratories Announces Board Changes

 
  
    #32
17.03.14 09:24
12:55 03.03.14


PR Newswire

BOSTON, Mar. 3, 2014

BOSTON, Mar. 3, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Donald H. Hunter, an executive and technology consultant with over 25 years of public company experience, has been appointed to its Board of Directors.  Mr. Hunter qualifies as a financial expert under the SEC guidelines, and will serve on the Company's audit committee.

"Donald Hunter brings a wealth of experience in accounting and control, financial reporting, mergers and acquisitions, international operations, and strategic planning.  We look forward to his contributions as a member of Columbia's Board of Directors," said Stephen G. Kasnet, Chairman of the Board.

Mr. Hunter is the Principal of Donald Hunter LLC, a consulting practice assisting investors and management to enhance the value of their companies.  He previously served as Chief Operating Officer and Chief Financial Officer of Harbor Global Company Limited from 2000 until 2006.  Prior to that, he was a senior executive with The Pioneer Group, Inc. for 12 years.  Mr. Hunter began his career at the General Electric Company, where he was a member of the Company's Corporate Audit Staff and a graduate of its Financial Management Training Program.  

Mr. Hunter is currently a director of the LGL Group and serves as its audit committee chairman.  He previously served as chairman of the audit committee of the Pioneer First Polish Trust Fund, the first mutual fund in Poland, and as a Member of the Board of several foreign subsidiaries.  He has an MBA with High Honors from Boston University.

The Company also announced that Edward A. Blechschmidt will not stand for re-election at the Company's upcoming annual meeting of stockholders in order to focus on his other activities.  Mr. Blechschmidt has been a director of Columbia since August 2004 and is Chairman of the Audit Committee.

"We are grateful to Ed for his long service on Columbia's Board, and his invaluable insight and guidance to the Company through its evolution and transformation to where we are today: a profitable company providing pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  We wish Ed well in his future endeavors," Mr. Kasnet concluded.    

About Columbia Laboratories

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  The Company has a successful heritage in pharmaceutical research and development, particularly in women's healthcare and drug delivery.  Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  For more information, please visit www.columbialabs.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are indicated by the words "may," "will," "plans," "believes," "expects," "anticipates," "potential," "should," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: Actavis' and Merck Serono's success in marketing CRINONE for use in infertility in their respective markets; changes in timing and quantity to Merck Serono's CRINONE supply orders; timely and successful renewals by Merck Serono of the license for CRINONE in major ex-U.S. markets; Merck Serono's success in gaining entry to new markets for CRINONE; the successful launch by Actavis of the next-generation vaginal progesterone product for the U.S. market; our ongoing ability to retain current and attract new customers; difficulties or delays in manufacturing; the availability and pricing of third-party sourced products and materials; successful compliance with FDA, MHRA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; changes in the laws and regulations; the ability to obtain and enforce patents and other intellectual property rights; the impact of patent expiration; the impact of competitive products and pricing; our inability to maintain effective internal controls over reporting; the strength of the United States dollar relative to international currencies, particularly the euro, British pound and the Swiss franc; competitive, economic, and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2012.  Columbia does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.

CRINONE® is a registered trademark of Actavis, Inc. in the U.S. and of Merck Serono S.A. outside the U.S.



Contact:







Jonathan Lloyd Jones


Tricia Truehart



Vice President & CFO
Senior Vice President

Columbia Laboratories, Inc.
The Trout Group LLC

(617) 639-1500


(646) 378-2593







SOURCE Columbia Laboratories, Inc.


Quelle: PR Newswire  

246459 Postings, 5865 Tage buranBOSTON, March 7, 2014

 
  
    #34
17.03.14 09:26
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis12:56 07.03.14


PR Newswire

BOSTON, March 7, 2014

BOSTON, March 7, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014.  The total purchase price was approximately $8.5 million.  This transaction reduces the total issued and outstanding shares of common stock by about 11.5% from approximately 12.15 million to 10.75 million.

"This was a unique opportunity for us to acquire Actavis' large block of shares at an advantageous price.  This action testifies to our solid financial position and our belief in Columbia's strong growth prospects," said Frank Condella, Columbia's president and CEO.  "Actavis continues its efforts behind CRINONE progesterone gel as seen with its recent launch of CRINONE NG.  We are confident that our long-standing relationship with Actavis will remain strong."

In conjunction with this transaction, G. Frederick Wilkinson has stepped down from the Board.  Mr. Wilkinson was initially appointed to Columbia's Board in July 2010 pursuant to the terms of an Investor's Rights Agreement, dated July 2, 2010, between Coventry and the Company, which granted Coventry the right to designate one director for election to the Board.

"We are grateful to Fred for his insight and support over the past four years on our Board," Condella noted.

About Columbia Laboratories

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  The Company has a successful heritage in pharmaceutical research and development, particularly in women's healthcare and drug delivery.  Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  For more information, please visit www.columbialabs.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are indicated by the words "may," "will," "plans," "believes," "expects," "anticipates," "potential," "should," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: Actavis' and Merck Serono's success in marketing CRINONE for use in infertility in their respective markets; changes in timing and quantity to Merck Serono's CRINONE supply orders; timely and successful renewals by Merck Serono of the license for CRINONE in major ex-U.S. markets; Merck Serono's success in gaining entry to new markets for CRINONE; the successful launch by Actavis of the next-generation vaginal progesterone product for the U.S. market; our ongoing ability to retain current and attract new customers; difficulties or delays in manufacturing; the availability and pricing of third-party sourced products and materials; successful compliance with FDA, MHRA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; changes in the laws and regulations; the ability to obtain and enforce patents and other intellectual property rights; the impact of patent expiration; the impact of competitive products and pricing; our inability to maintain effective internal controls over reporting; the strength of the United States dollar relative to international currencies, particularly the euro, British pound and the Swiss franc; competitive, economic, and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2013.  Columbia does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.

CRINONE® is a registered trademark of Actavis, Inc. in the U.S. and of Merck Serono S.A. outside the U.S.


Contact:  



Jonathon Lloyd Jones
Tricia Truehart

Vice President & CFO
Senior Vice President

Columbia Laboratories, Inc.
The Trout Group LLC

(617) 639-1500
(646) 378-2953


SOURCE Columbia Laboratories, Inc.


Quelle: PR Newswire
 

246459 Postings, 5865 Tage buranQuelle: PR Newswire

 
  
    #35
30.04.14 12:17
Molecular Profiles Expands Technology With GMP Hot Melt Extrusion
11:00 08.04.14

PR Newswire

NOTTINGHAM, England, April 8, 2014

NOTTINGHAM, England, April 8, 2014 /PRNewswire/ -- Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) has completed a significant investment into additional equipment as part of a wider project focusing on enabling technologies that facilitate processing of difficult-to-progress molecules.

The UK-based pharmaceutical development and manufacturing services provider has invested in GMP hot melt extrusion (HME) technology along with further milling equipment, enabling the Company to accelerate formulation development for its clients.

Dr Rob Harris, chief technical officer at Molecular Profiles, said: "Over the years, our company has gained a strong reputation in advanced characterisation, formulation development and dealing with complex molecules. We have been working in this space for nearly a decade, bringing a high level of understanding to, for instance, the stability and failings that occur in HME.

"Expanding our in-house equipment is all about complementing this expertise by bringing on-stream an even more diverse range of enabling technologies to assist clients in developing challenging compounds.

"Supported by our world-class suite of processing and characterisation tools, our new Enabling Technologies Division forms the backbone of our early formulation development services. Utilising a science-led approach, this team is primarily focused on screening formulation options for challenging molecules,  quickly developing effective formulations, and finding solutions to our clients' product development requirements," added Dr Harris.

This is the latest significant venture for Molecular Profiles, which opened its new clinical production site last July following a successful inspection from the Medicines and Healthcare products Regulatory Agency (MHRA).

Dovetailing with its development capabilities, the organisation manufactures a range of dosage forms for clinical trials spanning solids, liquids, semi-solids and inhaled products, including potent compounds.

Extending both its GMP and development equipment further strengthens the Company's ability to formulate a broader range of dosage forms which are able to deliver the drug substance more effectively.

The Company recently hosted a high-profile two-day conference focused on overcoming biological barriers in drug development.  The event was attended by dozens of pharmaceutical executives, scientists and leading academics from across the globe.

www.molprofiles.co.uk/ | enquiry@molprofiles.co.uk | https://twitter.com/MolProfiles

For further information, images and interview opportunities with Molecular Profiles, please contact Raman Sehgal at ramarketing | raman@ramarketingpr.com | 07808796300 | www.ramarketingpr.com | www.twitter.com/ramarketingpr

About Columbia Laboratories

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  The Company has a successful heritage in pharmaceutical research and development, particularly in women's healthcare and drug delivery.  Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  .For more information, please visit www.columbialabs.com.

CRINONE® is a registered trademark of Actavis, Inc. in the U.S. and of Merck Serono S.A. outside the U.S.

Molecular Profiles™ is a registered trademark of Molecular Profiles Ltd.

SOURCE Molecular Profiles Ltd.


Quelle: PR Newswire  

246459 Postings, 5865 Tage buranMolecular Profiles Strengthens US Presence

 
  
    #36
30.04.14 12:18
To Drive Growth
11:05 15.04.14

PR Newswire

NOTTINGHAM, England, April 15, 2014

NOTTINGHAM, England, April 15, 2014 /PRNewswire/ -- Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX), is set to increase awareness and uptake of its pharmaceutical development services in the North American market following the appointment of a new head of US sales.

The development and manufacturing services provider, which has a well-established track record for meeting objectives while tightening development timelines for its clients, has hired Charles D. Maher to expand its client base in the US.

Mr Maher brings extensive senior commercial experience in the global contract services market to this newly-created position. He will focus on presenting the benefits of Molecular Profiles' unique expertise in combining enabling technologies with advanced characterisation, formulation development and manufacturing.

The organisation recently created a new enabling technologies team and invested in GMP hot melt extrusion (HME) technology to further enhance its expertise in the processing of difficult-to-progress molecules.  Leveraging the location of its Boston-based parent company, Molecular Profiles expects its advanced knowledge in characterisation and dealing with complex molecules will resonate with many US firms.

Dr Nikin Patel, chief executive officer at Molecular Profiles, said: "Over the years, we have built a solid reputation in Europe for applying a science driven approach to our clients' development challenges in a cost-effective manner that delivers value by accelerating development. We are now striding toward executing our strategy to replicate this success in the United States.

"I am delighted to welcome Charles to the company. His extensive knowledge of the market, experience and strong industry contacts should benefit our efforts to capitalize on our state-of-the-art facility, manufacturing capabilities and growing suite of enabling technologies among pharmaceutical and biotech companies."

"Building our business in the US brings us closer to our current US-based customers and improves our service to them, while supporting our on-going initiative to expand our pharmaceutical development services client base."

Mr Maher has held senior roles in the sector and most recently was Vice President of Business Global Development/ USA and Europe for an international pharmaceutical R&D services company.

Along with its development capabilities, Molecular Profiles manufactures a range of dosage forms for clinical trials spanning solids, liquids, semi-solids and inhaled products, including potent compounds, from its MHRA-licensed site.

www.molprofiles.co.uk/ | enquiry@molprofiles.co.uk | https://twitter.com/MolProfiles

-ENDS-

For further information, images and interview opportunities with Molecular Profiles, please contact Raman Sehgal at ramarketing | raman@ramarketingpr.com | 07808796300 | www.ramarketingpr.com | www.twitter.com/ramarketingpr

About Columbia Laboratories

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  The Company has a successful heritage in pharmaceutical research and development, particularly in women's healthcare and drug delivery.  Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  For more information, please visit www.columbialabs.com.

CRINONE® is a registered trademark of Actavis, Inc. in the U.S. and of Merck Serono S.A. outside the U.S.

Molecular Profiles™ is a registered trademark of Molecular Profiles Ltd.

SOURCE Molecular Profiles Ltd.


Quelle: PR Newswire  

246459 Postings, 5865 Tage buranColumbia Laboratories to Discuss First Quarter

 
  
    #37
30.04.14 12:19
2014 Financial Results on April 29th Conference Call
12:55 17.04.14

PR Newswire

BOSTON, April 17, 2014

BOSTON, April 17, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on April 29, 2014, to discuss financial results of the first quarter ended March 31, 2014.  Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows:

Date:

Tuesday, April 29, 2014

Time:

8:30 am EDT

Dial-in numbers:

Toll free: (877) 870-4263 (U.S.) or  (855) 669-9657 (Canada)



International: (412) 317-0790

Conference ID:

10043722

Webcast (live & archive):

www.columbialabs.com, under 'Investor' or click here

The teleconference replay will be available approximately one hour after completion through Tuesday, May 6, 2014, at (877) 344-7529 (U.S.) or (412) 317-0088 (International). The conference ID for the replay is 10043722.  The archived webcast will be available for one year via the aforementioned URLs.

About Columbia Laboratories

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  The Company has a successful heritage in pharmaceutical research and development, particularly in women's healthcare and drug delivery.  Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  For more information, please visit www.columbialabs.com.

CRINONE® is a registered trademark of Actavis, Inc. in the U.S. and of Merck Serono S.A. outside the U.S.

Contact:



Jonathan Lloyd Jones



Vice President & CFO



Columbia Laboratories, Inc.



(617) 639-1500

SOURCE Columbia Laboratories, Inc.


Quelle: PR Newswire  

246459 Postings, 5865 Tage buranfirst quarter 2014

 
  
    #38
01.05.14 15:41

246459 Postings, 5865 Tage buranQuelle: PR Newswire

 
  
    #39
22.07.14 21:05
Columbia Laboratories Added to the Russell Microcap Index
14:05 26.06.14

PR Newswire

BOSTON, June 26, 2014

BOSTON, June 26, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that it has been added to the preliminary list for the Russell Microcap Index, to be finalized on June 27, 2014. The new membership lists for Russell Indexes are available at http://www.russell.com/indexes/tools-resources/reconstitution.asp.

The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.

"We are pleased to be added to the Russell Microcap Index, which we believe will raise our profile within the investment community and provide us with the opportunity to expand our shareholder base," said Frank Condella, CEO of Columbia Laboratories. "We have a successful history of developing pharmaceutical products, and are confident that the expansion of our pharmaceutical development services and the construction of an in-house product pipeline will build shareholder value."

Russell indexes are extensively used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Approximately $5.2 trillion in assets are benchmarked to them.

More information about Russell Indexes is available at http://www.russell.com/indexes.

About Columbia Laboratories

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  The Company has a successful heritage in developing pharmaceutical products, particularly in women's health.  Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  For more information, please visit www.columbialabs.com.

Forward Looking Statements

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are indicated by the words "may," "will," "plans," "believes," "expects," "anticipates," "potential," "should," and similar expressions, which are generally not historical in nature. These include all statements relating to expected financial performance and future business or product developments.  Management believes that these forward-looking statements are reasonable as and when made.  However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Columbia does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.  For a discussion of certain risks and uncertainties associated with Columbia's forward-looking statements, please review Columbia's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2013.  

Investor Relations Contact:

MBS Value Partners

Katja Buhrer

+212 661 7004

katja.buhrer@mbsvalue.com

SOURCE Columbia Laboratories, Inc.


Quelle: PR Newswire  

246459 Postings, 5865 Tage buran24.307 shares durche Nasdaq Lampe RT

 
  
    #40
22.07.14 21:06

246459 Postings, 5865 Tage buranund gleich weiter hier realtime ask Nasdaq

 
  
    #41
22.07.14 21:09
Preis pro share 6,38 $ Schleife 2.800 spread 0,95% buran und MfG und Vorsicht das U Boot taucht der Leuchtturm blinkt der Nasdaq Ticker springt und singt Dein Blitzer Depot Ding ..::hopshops  

246459 Postings, 5865 Tage buran14:37 23.07.14 news

 
  
    #42
23.07.14 15:50
Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call
14:37 23.07.14

PR Newswire

BOSTON, July 23, 2014

BOSTON, July 23, 2014 /PRNewswire/ -- The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on July 31, 2014, to discuss financial results for the second quarter ended June 30, 2014.  The call details are as follows:

Date:

Thursday, July 31, 2014

Time:

8:30 am EDT

Dial-in numbers:

Toll free: (877) 870-4263 (U.S.), (855) 669-9657 (Canada) or,



International: (412) 317-0790

Webcast (live & archive):

www.columbialabs.com, under 'Investor' or click here

The teleconference replay will be available approximately one hour after completion through Thursday, August 7, 2014, at (877) 344-7529 (U.S.), (855) 669-9658 (Canada) or (412) 317-0088 (International). The conference ID for the replay is 10049906.  The archived webcast will be available for one year via the aforementioned URLs.

About Columbia Laboratories

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  The Company has a successful heritage in developing pharmaceutical products, particularly in women's health.  Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  For more information, please visit www.columbialabs.com.

CRINONE® is a registered trademark of Actavis, Inc. in the U.S.

Contact:

MBS Value Partners

Katja Buhrer

+212 661 7004

katja.buhrer@mbsvalue.com

SOURCE Columbia Laboratories, Inc.


Quelle: PR Newswire  

246459 Postings, 5865 Tage buranWebsite

 
  
    #43
24.07.14 12:07
www.columbialabs.com

buran und MfG und Tüddel Büddel  

246459 Postings, 5865 Tage burannews 13:05 31.07.14

 
  
    #44
31.07.14 15:41
Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis
13:05 31.07.14

PR Newswire

BOSTON and NOTTINGHAM, England, July 31, 2014

BOSTON and NOTTINGHAM, England, July 31, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., and XenoGesis Ltd., have announced a collaboration that will support pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage.  Molecular Profiles' pharmaceutical development services will be supported by XenoGesis' expertise in preclinical drug metabolism and pharmacokinetics (DMPK) to give clients a smarter route into formulation development and a better understanding of a compound's bioavailability.  This strategic alliance will allow the Nottingham-based companies to help drug developers in the initial design and selection of compounds for key DMPK and ADME (absorption, distribution, metabolism and elimination) studies, as well as supporting lead candidates which have solubility issues during formulation development.

"We are very pleased to have struck this collaboration with the team at XenoGesis," said Frank Condella, President and Chief Executive Officer of Columbia Laboratories. "We have complementary service offerings which allow us to apply a science-driven, collective approach to overcome the complexities of challenging molecules. It also adds a vital pK service to our enabling technologies package.

"For us, this will build-upon the very successful drug development alliances we already have in place. We can now seamlessly offer a comprehensive service from initial drug discovery through to clinical supplies with best-in-class companies," concluded Mr. Condella.

XenoGesis was founded by its managing director, Richard Weaver Ph.D., after a 15-year career at AstraZeneca. The company specializes in studying research compounds from a chemical and biological perspective to inform clients on how they will behave in the body.

Dr. Weaver commented, "Combining our skills in DMPK with the chemical knowledge at Molecular Profiles will provide a solid platform to support clients.  We will be able to give them a better understanding of their compounds during pre-clinical work, which in turn, will reduce cost and provide a quicker route to market."

Working with leading drug development companies across the world, Columbia Laboratories' Molecular Profiles subsidiary specializes in advanced characterisation, pharmaceutical product development, clinical trials manufacturing and analytical support.  The company recently created a new enabling technologies team and invested in GMP hot melt extrusion (HME) technology at its clinical manufacturing facility to further enhance its expertise in the processing of difficult-to-progress molecules.

Alongside its development capabilities, its MHRA-licensed site enables the company to manufacture a range of dosage forms for clinical trials spanning solids, liquids, semi-solids and inhaled products, including potent compounds and controlled drugs.

About Columbia Laboratories

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  The Company has a successful heritage in pharmaceutical research and development, particularly in women's healthcare and drug delivery.  Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  For more information, please visit www.columbialabs.com.

About Molecular Profiles

Molecular Profiles Ltd., a wholly owned subsidiary of Columbia Laboratories, Inc., is a contract development and manufacturing organization (CDMO) that specializes in early phase pharmaceutical development. Its early phase services extend from pre-formulation and formulation development to clinical trial manufacturing, with specialist knowledge on developing challenging molecules and complex compounds.  Molecular Profiles is also renowned for its expertise and toolkit to analytically resolve some of the toughest issues during development and relating to intellectual property issues. The company's services are dedicated to pharmaceutical, biopharmaceutical and healthcare companies across the globe. For more information please visit www.molprofiles.co.uk

About XenoGesis

XenoGesis Limited, a contract research organization (CRO), specializes in expert DMPK/ADME laboratory services and interpretation and Drug Discovery consultancy.  The XenoGesis team has significant experience and a track record of delivering candidate drugs to man from their careers at AstraZeneca R&D Charnwood.  XenoGesis supports the Drug Discovery activities of Biotechnology and Pharmaceutical companies and academic units.  For more information please visit www.xenogesis.com

Investor Relations Contact:

MBS Value Partners

Katja Buhrer or Betsy Brod

+212 661 7004

katja.buhrer@mbsvalue.com

SOURCE Columbia Laboratories, Inc.


Quelle: PR Newswire  

246459 Postings, 5865 Tage buranReports-Second-Quarter-2014-Financial-Results

 
  
    #45
31.07.14 15:41

246459 Postings, 5865 Tage buranBOSTON, Aug. 6, 2014

 
  
    #46
07.08.14 03:42
Columbia Laboratories Announces Sale Of IP And Technology For Legatrin P.M. To Lil' Drug Store Products
14:35 06.08.14

PR Newswire

BOSTON, Aug. 6, 2014

BOSTON, Aug. 6, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that Lil' Drug Store Products exercised its option to purchase the Intellectual Property Rights and Technology related to Legatrin P.M. Columbia licensed this product to Lil' Drug Store Products approximately fourteen years ago and has received annual royalties. Based on a predetermined formula, Columbia will receive approximately $2.2 million for the sale.

"Columbia has a long history of developing products for other companies and licensing the product and associated IP to commercial partners. We are pleased to have completed this transaction which enables us to monetize our royalty stream and strengthen our balance sheet," said Frank Condella, President and Chief Executive Officer of Columbia Laboratories.

About Columbia Laboratories

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry. The Company has a successful heritage in pharmaceutical research and development, particularly in women's healthcare and drug delivery. Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide. For more information, please visit www.columbialabs.com.

Investor Relations Contact:

MBS Value Partners

Katja Buhrer or Betsy Brod

+212 661 7004

katja.buhrer@mbsvalue.com

SOURCE Columbia Laboratories, Inc.


Quelle: PR Newswire  

246459 Postings, 5865 Tage buran17,5 Kilo durche Nasdaq Laterne TOP

 
  
    #47
18.08.14 22:58

1718 Postings, 5169 Tage Basesieht gut heute aus

 
  
    #48
28.10.14 18:22
so kann es weiter gehen  

246459 Postings, 5865 Tage buran.Mario Meierhof 29. September um 21:38

 
  
    #49
28.10.14 20:07
buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…

Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof  

246459 Postings, 5865 Tage buranCommission

 
  
    #50
18.12.14 22:40
Die Commission (Kommission) ist eine Provision, welche ein Broker für seine Vermittlungstätigkeit erhält. Sie wird für den Kauf und Verkauf gemeinsam erhoben (round turn commission). http://www.ariva.de/extras/lexikon.m?begriff=Commission
 

246459 Postings, 5865 Tage buran2.999 Glitzerlinge durche Nasdaq Laterne geblitzt

 
  
    #51
09.01.15 21:38

246459 Postings, 5865 Tage buranColumbia: Our mission,your dream

 
  
    #52
21.12.16 10:00
kein aktueller Kurs verfügbar ,GrB
 

246459 Postings, 5865 Tage buranbestätigen

 
  
    #53
17.05.17 14:46
kein aktueller Kurs verfügbar ,GrB
 

246459 Postings, 5865 Tage buranlinke Spur

 
  
    #54
26.09.17 14:33
Beiträge: 54
Zugriffe: 12.946 / Heute: 8

GrB  

10 Postings, 144 Tage SarahkciiaLöschung

 
  
    #55
25.04.21 02:47

Moderation
Zeitpunkt: 26.04.21 11:11
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Spam

 

 

Seite: < 1 | 2 | 3 >  
   Antwort einfügen - nach oben